LGALS1 and hepatocellular carcinoma: Previous reports have identified the overexpression of Gal-1 in HCC to trigger epithelial-mesenchymal transition (EMT) and also allowing cells to become resistant to sorafenib through the PI3K/Akt signaling [11].